207 related articles for article (PubMed ID: 10686061)
1. Assessment of needs for plasma for fractionation in Europe.
Burckhardt JJ
Biologicals; 1999 Dec; 27(4):337-41. PubMed ID: 10686061
[TBL] [Abstract][Full Text] [Related]
2. Effect of viral nucleic acid testing on contamination frequency of manufacturing plasma pools.
Nübling CM; Unkelbach U; Chudy M; Seitz R
Transfusion; 2008 May; 48(5):822-6. PubMed ID: 18208414
[TBL] [Abstract][Full Text] [Related]
3. Impact of nucleic acid testing for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus on the safety of blood supply in Italy: a 6-year survey.
Velati C; Romanò L; Fomiatti L; Baruffi L; Zanetti AR;
Transfusion; 2008 Oct; 48(10):2205-13. PubMed ID: 18631163
[TBL] [Abstract][Full Text] [Related]
4. Reducing the risk of infection from plasma products: specific preventative strategies.
Burnouf T; Radosevich M
Blood Rev; 2000 Jun; 14(2):94-110. PubMed ID: 11012252
[TBL] [Abstract][Full Text] [Related]
5. Safety issues for plasma derivatives and benefit from NAT testing.
Willkommen H; Schmidt I; Löwer J
Biologicals; 1999 Dec; 27(4):325-31. PubMed ID: 10686059
[TBL] [Abstract][Full Text] [Related]
6. External quality assessment for the detection of blood-borne viruses in plasma by nucleic acid amplification technology: the first human immunodeficiency virus and hepatitis B virus studies (HIV EQA/1 and HBV EQA/1) and the fifth hepatitis C virus study (HCV EQA/5).
Pisani G; Cristiano K; Saldanha J; Wirz M; Bisso GM; Mele C; Gentili G;
Vox Sang; 2004 Aug; 87(2):91-5. PubMed ID: 15355499
[TBL] [Abstract][Full Text] [Related]
7. Detection of HCV and HIV-1 antibody negative infections in Scottish and Northern Ireland blood donations by nucleic acid amplification testing.
Jarvis LM; Dow BC; Cleland A; Davidson F; Lycett C; Morris K; Webb B; Jordan A; Petrik J
Vox Sang; 2005 Oct; 89(3):128-34. PubMed ID: 16146504
[TBL] [Abstract][Full Text] [Related]
8. Experience of German Red Cross blood donor services with nucleic acid testing: results of screening more than 30 million blood donations for human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus.
Hourfar MK; Jork C; Schottstedt V; Weber-Schehl M; Brixner V; Busch MP; Geusendam G; Gubbe K; Mahnhardt C; Mayr-Wohlfart U; Pichl L; Roth WK; Schmidt M; Seifried E; Wright DJ;
Transfusion; 2008 Aug; 48(8):1558-66. PubMed ID: 18466173
[TBL] [Abstract][Full Text] [Related]
9. Should HBV DNA NAT replace HBsAg and/or anti-HBc screening of blood donors?
Busch MP
Transfus Clin Biol; 2004 Feb; 11(1):26-32. PubMed ID: 14980546
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of a new molecular assay for detection of human immunodeficiency virus type 1 RNA, hepatitis C virus RNA, and hepatitis B virus DNA.
McCormick MK; Dockter J; Linnen JM; Kolk D; Wu Y; Giachetti C
J Clin Virol; 2006 Jul; 36(3):166-76. PubMed ID: 16427802
[TBL] [Abstract][Full Text] [Related]
11. NAT: perspectives for cellular components.
Barbara JA
Biologicals; 1999 Dec; 27(4):333-6. PubMed ID: 10686060
[TBL] [Abstract][Full Text] [Related]
12. Analytical and clinical sensitivity of the Procleix Ultrio HIV-1/HCV/HBV assay in samples with a low viral load.
Katsoulidou A; Moschidis Z; Sypsa V; Chini M; Papatheodoridis GV; Tassopoulos NC; Mimidis K; Karafoulidou A; Hatzakis A
Vox Sang; 2007 Jan; 92(1):8-14. PubMed ID: 17181585
[TBL] [Abstract][Full Text] [Related]
13. A pilot study for screening blood donors in Taiwan by nucleic acid amplification technology: detecting occult hepatitis B virus infections and closing the serologic window period for hepatitis C virus.
Li L; Chen PJ; Chen MH; Chak KF; Lin KS; Tsai SJ
Transfusion; 2008 Jun; 48(6):1198-206. PubMed ID: 18422856
[TBL] [Abstract][Full Text] [Related]
14. Impact of individual-donation nucleic acid testing on risk of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission by blood transfusion in South Africa.
Vermeulen M; Lelie N; Sykes W; Crookes R; Swanevelder J; Gaggia L; Le Roux M; Kuun E; Gulube S; Reddy R
Transfusion; 2009 Jun; 49(6):1115-25. PubMed ID: 19309474
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of an automated high-volume extraction method for viral nucleic acids in comparison to a manual procedure with preceding enrichment.
Hourfar MK; Schmidt M; Seifried E; Roth WK
Vox Sang; 2005 Aug; 89(2):71-6. PubMed ID: 16101686
[TBL] [Abstract][Full Text] [Related]
16. Residual risk of transfusion-transmitted viral infections in Shenzhen, China, 2001 through 2004.
Shang G; Seed CR; Wang F; Nie D; Farrugia A
Transfusion; 2007 Mar; 47(3):529-39. PubMed ID: 17319836
[TBL] [Abstract][Full Text] [Related]
17. Status of NAT screening for HCV, HIV and HBV: experience in Japan.
Tomono T; Murokawa H; Minegishi K; Yamanaka R; Lizuka HY; Miyamoto M; Satoh S; Nakahira S; Murozuka T; Emura H; Doi Y; Mine H; Yokoyama S; Ohnuma H; Tanaka T; Yoshikawa A; Nishioka K;
Dev Biol (Basel); 2002; 108():29-39. PubMed ID: 12220140
[TBL] [Abstract][Full Text] [Related]
18. Nucleic acid amplification technology screening for hepatitis C virus and human immunodeficiency virus for blood donations.
Bamaga MS; Bokhari FF; Aboud AM; Al-Malki M; Alenzi FQ
Saudi Med J; 2006 Jun; 27(6):781-7. PubMed ID: 16758035
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of Parvovirus B19 and Hepatitis A virus in Portuguese blood donors.
Henriques I; Monteiro F; Meireles E; Cruz A; Tavares G; Ferreira M; Araújo F
Transfus Apher Sci; 2005 Nov; 33(3):305-9. PubMed ID: 16203176
[TBL] [Abstract][Full Text] [Related]
20. Sensitivity of two hepatitis B virus, hepatitis C virus (HCV), and human immunodeficiency virus (HIV) nucleic acid test systems relative to hepatitis B surface antigen, anti-HCV, anti-HIV, and p24/anti-HIV combination assays in seroconversion panels.
Assal A; Barlet V; Deschaseaux M; Dupont I; Gallian P; Guitton C; Morel P; van Drimmelen H; David B; Lelie N; De Micco P
Transfusion; 2009 Feb; 49(2):301-10. PubMed ID: 19389212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
